Provectus Biopharmaceuticals (PVCT) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S. Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,522,119
Entity Information, Former Legal or Registered Name	Not Applicable

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 367,250	$ 21,605
Restricted cash	1,042,957	1,410,102
Short-term receivables	947	394
Prepaid expenses and other current assets	181,180	467,081
Total Current Assets	1,592,334	1,899,182
Equipment and furnishings, less accumulated depreciation of $108,764 and $102,073, respectively	14,250	20,941
Operating lease right-of-use asset	83,509	117,123
Total Assets	1,690,093	2,037,246
Current Liabilities:
Accounts payable	1,785,322	2,094,258
Unearned grant revenue	1,074,358	1,510,958
Other accrued expenses	3,057,678	2,404,012
Accrued interest	13,867	30,844
Accrued interest - related parties	122,646	40,992
Notes payable	78,066	239,394
Convertible notes payable	775,000	625,000
Operating lease liability, current portion	47,146	44,422
Total Current Liabilities	9,171,583	8,192,380
Operating lease liability, non-current portion	37,714	73,376
Total Liabilities	9,209,297	8,265,756
Commitments, contingencies, and litigations (Note 12)
Stockholders’ Deficit:
Preferred stock, value
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,522,119 and 419,497,119 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	419,522	419,497
Additional paid-in capital	244,101,958	242,954,193
Accumulated other comprehensive loss	(36,207)	(35,679)
Accumulated deficit	(252,026,996)	(249,588,641)
Total Stockholders’ Deficit	(7,519,204)	(6,228,510)
Total Liabilities and Stockholders’ Deficit	1,690,093	2,037,246
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	12,373	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	10,146	9,747
Related Party [Member]
Current Liabilities:
Convertible notes payable - related parties	$ 2,217,500	$ 1,202,500

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accumulated depreciation, equipment and furnishings	$ 108,764	$ 102,073
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	419,522,119	419,497,119
Common stock, shares outstanding	419,522,119	419,497,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred stock, shares issued	12,373,247	12,373,247
Preferred stock, shares outstanding	12,373,247	12,373,247
Preferred stock, liquidation preference value	$ 14,164,889	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	11,241,000	11,241,000
Preferred stock, shares issued	10,146,818	9,746,626
Preferred stock, shares outstanding	10,146,818	9,746,626
Preferred stock, liquidation preference value	$ 116,160,245	$ 111,578,880

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Grant Revenue	$ 69,733	$ 314,890	$ 436,600	$ 824,205
Operating Expenses:
Research and development	350,792	580,390	1,333,399	2,068,154
General and administrative	433,089	400,689	1,399,765	1,500,278
Total Operating Expenses	783,881	981,079	2,733,164	3,568,432
Total Operating Loss	(714,148)	(666,189)	(2,296,564)	(2,744,227)
Other Income/(Expense):
Research and development tax credit	(167)	(638)	15,798	37,621
Interest expense, net	(61,524)	(46,440)	(157,589)	(115,424)
Total Other Income (Expense), Net	(61,691)	(47,078)	(141,791)	(77,803)
Net Loss	$ (775,839)	$ (713,267)	$ (2,438,355)	$ (2,822,030)
Net Loss per share - basic	$ 0	$ 0	$ (0.01)	$ (0.01)
Net Loss per share - diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average number of shares - basic	419,515,869	419,489,239	419,503,438	419,461,313
Weighted average number of shares - diluted	419,515,869	419,489,239	419,503,438	419,461,313

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Loss	$ (775,839)	$ (713,267)	$ (2,438,355)	$ (2,822,030)
Other Comprehensive Loss:
Foreign currency translation adjustments		(1,241)	(441)	(2,285)
Total Comprehensive Loss	$ (775,839)	$ (714,508)	$ (2,438,796)	$ (2,824,315)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series D-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 12,373	$ 9,219	$ 419,447	$ 241,440,106	$ (34,467)	$ (246,033,958)	$ (4,187,280)
Balance, shares at Dec. 31, 2021	12,373,247	9,218,449	419,447,119
Net loss						(1,030,922)	(1,030,922)
Other comprehensive income					(716)		(716)
Series D-1 Preferred Stock issued for cash		$ 52		149,948			150,000
Series D-1 Preferred Stock issued for cash, shares		52,411
Balance at Mar. 31, 2022	$ 12,373	$ 9,271	$ 419,447	241,590,054	(35,183)	(247,064,880)	(5,068,918)
Balance, shares at Mar. 31, 2022	12,373,247	9,270,860	419,447,119
Balance at Dec. 31, 2021	$ 12,373	$ 9,219	$ 419,447	241,440,106	(34,467)	(246,033,958)	(4,187,280)
Balance, shares at Dec. 31, 2021	12,373,247	9,218,449	419,447,119
Net loss							(2,822,030)
Balance at Sep. 30, 2022	$ 12,373	$ 9,271	$ 419,497	241,593,029	(36,752)	(248,855,988)	(6,858,570)
Balance, shares at Sep. 30, 2022	12,373,247	9,270,860	419,497,119
Balance at Mar. 31, 2022	$ 12,373	$ 9,271	$ 419,447	241,590,054	(35,183)	(247,064,880)	(5,068,918)
Balance, shares at Mar. 31, 2022	12,373,247	9,270,860	419,447,119
Net loss						(1,077,841)	(1,077,841)
Other comprehensive income					(328)		(328)
Balance at Jun. 30, 2022	$ 12,373	$ 9,271	$ 419,447	241,590,054	(35,511)	(248,142,721)	(6,147,087)
Balance, shares at Jun. 30, 2022	12,373,247	9,270,860	419,447,119
Net loss						(713,267)	(713,267)
Other comprehensive income					(1,241)		(1,241)
Common Stock			$ 50	2,975			3,025
Common stock, shares			50,000
Balance at Sep. 30, 2022	$ 12,373	$ 9,271	$ 419,497	241,593,029	(36,752)	(248,855,988)	(6,858,570)
Balance, shares at Sep. 30, 2022	12,373,247	9,270,860	419,497,119
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	242,954,193	(35,679)	(249,588,641)	(6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Conversion of 2021 Note to Series D1 Preferred Stock		$ 18		53,992			54,010
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		18,872
Net loss						(827,454)	(827,454)
Other comprehensive income					191		191
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	242,954,193	(35,679)	(249,588,641)	(6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Net loss							(2,438,355)
Balance at Sep. 30, 2023	$ 12,373	$ 10,146	$ 419,522	244,101,958	(36,207)	(252,026,996)	(7,519,204)
Balance, shares at Sep. 30, 2023	12,373,247	10,146,818	419,522,119
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Conversion of 2021 Note to Series D1 Preferred Stock		$ 189		540,033			540,222
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		188,757
Net loss						(835,062)	(835,062)
Other comprehensive income					(278)		(278)
Balance at Jun. 30, 2023	$ 12,373	$ 9,954	$ 419,497	243,548,218	(35,766)	(251,251,157)	(7,296,881)
Balance, shares at Jun. 30, 2023	12,373,247	9,954,255	419,497,119
Conversion of 2021 Note to Series D1 Preferred Stock		$ 122		351,110			351,232
Conversion of 2021 Note to Series D-1 Preferred Stock, shares		122,725
Net loss						(775,839)	(775,839)
Other comprehensive income					(441)		(441)
Common stock issued for services			25	2,825			2,850
Common stock issued for services, shares		25,000
Conversion of 2022 Note to Series D1 Preferred Stock		$ 70		199,805			199,875
Conversion of 2022 Note to Series D-1 Preferred Stock, shares		69,838
Balance at Sep. 30, 2023	$ 12,373	$ 10,146	$ 419,522	$ 244,101,958	$ (36,207)	$ (252,026,996)	$ (7,519,204)
Balance, shares at Sep. 30, 2023	12,373,247	10,146,818	419,522,119

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows From Operating Activities:
Net loss	$ (2,438,355)	$ (2,822,030)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,850	3,025
Non-cash lease expense	33,613	41,947
Depreciation	6,691	8,857
Changes in operating assets and liabilities
Short term receivables	(553)	4,351
Prepaid expenses and other current assets	359,572	142,129
Accounts payable	(308,728)	654,017
Unearned grant revenue	(436,600)	(824,205)
Other accrued expenses	653,664	442,355
Operating lease liability	(32,938)	(47,664)
Accrued interest	150,017	110,536
Net Cash Used In Operating Activities	(2,010,767)	(2,286,682)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	700,000	550,000
Proceeds from issuance of convertible notes payable - related parties	1,525,000	510,000
Repayment of short-term note payable	(234,997)	(166,317)
Net Cash Provided By Financing Activities	1,990,003	893,683
Effect of exchange rates on cash and restricted cash	(736)	(2,592)
Net Decrease In Cash and Restricted Cash	(21,500)	(1,395,591)
Cash and Restricted Cash, Beginning of Period	1,431,707	3,106,942
Cash and Restricted Cash, End of Period	1,410,207	1,711,351
Cash and cash equivalents	367,250	67,030
Restricted cash	1,042,957	1,644,321
Non-cash investing and financing activities:
For purchase of Series D-1 Preferred Stock		(150,000)
Right-of-use assets obtained in exchange for operating lease liabilities		130,422
Conversion of 2021 Notes and related accrued interest to Series D-1 Preferred Stock	804,533
Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock	170,126
Purchase of insurance policies financed by short-term note payable	$ (73,669)	$ (57,146)

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration. The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair, depending on the disease being treated and the concentration of the RBS utilized in the treatment. Second, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both. The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov. The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%. The Company’s small molecule HX medical science platform comprises several different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo in vitro Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s cash and restricted cash were $ 1,410,207 1,042,957 7,579,249 6,293,198 2,438,355 2,822,030 2,010,767 2,286,682 The Company plans to access capital resources through possible public or private equity offerings, including the 2022 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although there can be no assurance that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, there can be no assurance that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2023 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, there can be no assurance that it will be able to complete additional financing in a timely manner. Any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2022 consolidated financial statements were issued in its 2022 Annual Report on March 30, 2023, there have been no material changes to the Company’s significant accounting policies. Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets. Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of September 30, 2023 is $ 1,042,957 Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,160,207 1,181,707 Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2023 2022 September 30, 2023 2022 Warrants 437,500 487,500 Options 3,225,000 3,425,000 Convertible preferred stock 113,841,427 105,081,847 2021 unsecured convertible notes 817,766 8,602,376 2022 unsecured convertible notes 10,115,192 646,952 Total potentially dilutive shares 128,636,885 118,243,675 Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Other Accrued Expenses

Other Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at September 30, 2023 and December 31, 2022: Schedule of Other Accrued Expenses September 30, December 31, 2023 2022 Accrued payroll and taxes $ 611,646 $ 314,160 Accrued vacation 88,691 69,077 Accrued directors’ fees 2,234,339 1,945,589 Accrued other expenses 123,002 75,186 Total Other Accrued Expenses $ 3,057,678 $ 2,404,012

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2023 $ 550,000 $ 525,000 $ 1,075,000 Conversion (50,000 ) - (50,000 ) Balance as of March 31, 2023 500,000 525,000 1,025,000 Conversion (500,000 ) - (500,000 ) Balance as of June 30, 2023 - 525,000 525,000 Balance - 525,000 525,000 Conversion - (325,000 ) (325,000 ) Issued Balance as of September 30, 2023 $ - $ 200,000 $ 200,000 Through September 30, 2023, the Company issued 2021 Notes with aggregate proceeds of $ 1,075,000 525,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2023 $ 75,000 $ 677,500 $ 752,500 Balance $ 75,000 $ 677,500 $ 752,500 Issued - 600,000 600,000 Balance as of March 31, 2023 75,000 1,277,500 1,352,500 Balance 75,000 1,277,500 1,352,500 Issued - 725,000 725,000 Balance as of June 30, 2023 75,000 2,002,500 2,077,500 Balance 75,000 2,002,500 2,077,500 Issued 700,000 200,000 900,000 Conversion - (185,000 ) (185,000 ) Balance as of September 30, 2023 $ 775,000 $ 2,017,500 $ 2,792,500 Balance $ 775,000 $ 2,017,500 $ 2,792,500 Through September 30, 2023, the Company issued 2022 Notes with aggregate proceeds of $ 2,977,500 2,202,500 For further details on the terms of the 2021 and 2022 Notes, refer to our Form 10-K as filed with the SEC on March 30, 2023. 2023 Conversions of 2021 Notes into Preferred Stock The following summarizes the conversion activity during the nine months ended September 30, 2023: Schedule of Conversion of Notes into Preferred Stock Series D-1 Preferred Stock Principal converted $ 875,000 Accrued interest converted 70,466 Total converted $ 945,466 Conversion price $ 2.862 Total shares 330,354 During the three months ended September 30, 2023, principal and interest in the aggregate amount of $ 351,239 122,725 2.862 During the nine months ended September 30, 2023, principal and interest in the aggregate amount of $ 945,466 330,354 2.862 2023 Conversions of 2022 Notes into Preferred Stock The following summarizes the conversion activity during the nine months ended September 30, 2023: Series D-1 Preferred Stock Principal converted $ 185,000 Accrued interest converted 14,875 Total converted $ 199,875 Conversion price $ 2.862 Total shares 69,838 During the three and nine months ended September 30, 2023, principal and interest in the aggregate amount of $ 199,875 69,838 2.862

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of September 30, 2023 and December 31, 2022, the balance of the note payable was $ 78,066 239,394

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended September 30, 2023 and 2022, the Company had consulting fees of $ 63,600 18,750 During the nine months ended September 30, 2023 and 2022, the Company had consulting fees of $ 190,800 56,250 Accrued director fees for Mr. Bruce Horowitz as of September 30, 2023 and December 31, 2022 were $ 412,500 356,250 381,600 212,000 See Note 5 for details of other related party transactions. Director fees during the three and nine months ended September 30, 2023 and 2022 were $ 96,250 288,750 2,234,339 1,945,589

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Preferred Stock During the nine months ended September 30, 2023, the Company issued 330,354 875,000 70,466 During the nine months ended September 30, 2023, the Company issued 69,838 185,000 14,875 Options During the three and nine months ended September 30, 2023 and 2022, the Company did not have any issuances, grants, or exercises of options. The following table summarizes option activities during the nine months ended September 30, 2023: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2023 3,425,000 $ 0.29 $ - Forfeited (200,000 ) 0.67 Outstanding and exercisable at September 30, 2023 3,225,000 0.27 2.11 $ - The following table summarizes information about options outstanding and exercisable at September 30, 2023: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 2.10 $ - $ 0.29 100,000 2.10 $ - $ 0.75 550,000 2.20 $ - $ 0.88 150,000 0.80 $ - 3,225,000 2.11 $ - Warrants During the three and nine months ended September 30, 2023 and 2022, the Company did not have any issuances, grants, or exercises of warrants. The following table summarizes warrant activities during the nine months ended September 30, 2023: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2023 475,000 $ 0.97 Forfeited (37,500 ) 0.29 Outstanding and exercisable at September 30, 2023 437,500 $ 1.03 0.60 $ - The following table summarizes information about warrants outstanding and exercisable at September 30, 2023: Summary of Warrants Outstanding Exercise Price Outstanding and Exercisable Weighted Average Intrinsic Value $ 0.29 50,000 0.29 $ - $ 1.00 18,000 0.64 $ - $ 1.12 366,000 0.64 $ - $ 2.00 3,500 0.64 $ - 437,500 0.60 $ - Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions. Annual Stockholder Meeting Proposals The Company held its annual meeting of stockholders on June 21, 2023. Stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	9. Leases The Company leased 4,500 five years 6,100 On June 30, 2022, the lease expired and was not renewed. On June 18, 2022, the company leased 2,700 three years 4,053 4,278 Total operating lease expense for the three months ended September 30, 2023 was $ 12,560 8,373 4,187 12,497 8,331 4,166 Total operating lease expense for the nine months ended September 30, 2023 was $ 38,739 25,826 12,913 50,548 33,698 16,850 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 32,938 $ 50,784 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 130,422 Weighted Average Remaining Lease Term Operating leases 1 year 9 months 2 years 9 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2023 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2023 $ 12,497 2024 50,663 2025 25,668 Total lease payments 88,828 Less: amount representing imputed interest (3,968 ) Present value of lease liability 84,860 Less: current portion (47,146 ) Lease liability, non-current portion $ 37,714

Grants

Grants	9 Months Ended
	Sep. 30, 2023
Grants
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 As of September 30, 2023 and December 31, 2022, $ 1,074,358 1,510,958 69,733 436,600 314,890 824,205

License Transactions

License Transactions	9 Months Ended
	Sep. 30, 2023
License Transactions
License Transactions	11. License Transactions On February 16, 2022, and later amended on May 11, 2022, the Company entered into an option agreement with the University of Miami (“UM”) for an exclusive worldwide license of intellectual property (“IP”) developed by the Ophthalmic Biophysics Center (“OBC”) of Bascom Palmer Eye Institute (“BPEI”) that included the use of OBC’s ophthalmic photodynamic antimicrobial therapy (“PDAT”) medical device in combination with formulations of the Company’s pharmaceutical-grade RBS for the treatment of bacterial, fungal, and viral infections of the eye. The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company (i) paid $5,000 for the option to obtain an exclusive worldwide, royalty-bearing license that had an option expiration date of May 31, 2023, (ii) agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option, (iii) agreed to pay up to $25,000 of past UM patent expenses for this IP, and (iv) entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis

Commitments, Contingencies and

Commitments, Contingencies and Litigation	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	12. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Convertible Notes Payable Subsequent to September 30, 2023, the Company entered into a 2022 Note with a non-related party investor in the aggregate principal amount of $ 50,000 Series D-1 Preferred Stock Subsequent to September 30, 2023, principal and interest in the aggregate amount of $ 289,101 101,061 2.862

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets.
Restricted Cash	Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of September 30, 2023 is $ 1,042,957
Cash Concentrations	Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,160,207 1,181,707
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2023 2022 September 30, 2023 2022 Warrants 437,500 487,500 Options 3,225,000 3,425,000 Convertible preferred stock 113,841,427 105,081,847 2021 unsecured convertible notes 817,766 8,602,376 2022 unsecured convertible notes 10,115,192 646,952 Total potentially dilutive shares 128,636,885 118,243,675
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2023 2022 September 30, 2023 2022 Warrants 437,500 487,500 Options 3,225,000 3,425,000 Convertible preferred stock 113,841,427 105,081,847 2021 unsecured convertible notes 817,766 8,602,376 2022 unsecured convertible notes 10,115,192 646,952 Total potentially dilutive shares 128,636,885 118,243,675

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at September 30, 2023 and December 31, 2022: Schedule of Other Accrued Expenses September 30, December 31, 2023 2022 Accrued payroll and taxes $ 611,646 $ 314,160 Accrued vacation 88,691 69,077 Accrued directors’ fees 2,234,339 1,945,589 Accrued other expenses 123,002 75,186 Total Other Accrued Expenses $ 3,057,678 $ 2,404,012

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2023 $ 550,000 $ 525,000 $ 1,075,000 Conversion (50,000 ) - (50,000 ) Balance as of March 31, 2023 500,000 525,000 1,025,000 Conversion (500,000 ) - (500,000 ) Balance as of June 30, 2023 - 525,000 525,000 Balance - 525,000 525,000 Conversion - (325,000 ) (325,000 ) Issued Balance as of September 30, 2023 $ - $ 200,000 $ 200,000 Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2023 $ 75,000 $ 677,500 $ 752,500 Balance $ 75,000 $ 677,500 $ 752,500 Issued - 600,000 600,000 Balance as of March 31, 2023 75,000 1,277,500 1,352,500 Balance 75,000 1,277,500 1,352,500 Issued - 725,000 725,000 Balance as of June 30, 2023 75,000 2,002,500 2,077,500 Balance 75,000 2,002,500 2,077,500 Issued 700,000 200,000 900,000 Conversion - (185,000 ) (185,000 ) Balance as of September 30, 2023 $ 775,000 $ 2,017,500 $ 2,792,500 Balance $ 775,000 $ 2,017,500 $ 2,792,500
Schedule of Conversion of Notes into Preferred Stock	The following summarizes the conversion activity during the nine months ended September 30, 2023: Schedule of Conversion of Notes into Preferred Stock Series D-1 Preferred Stock Principal converted $ 875,000 Accrued interest converted 70,466 Total converted $ 945,466 Conversion price $ 2.862 Total shares 330,354 The following summarizes the conversion activity during the nine months ended September 30, 2023: Series D-1 Preferred Stock Principal converted $ 185,000 Accrued interest converted 14,875 Total converted $ 199,875 Conversion price $ 2.862 Total shares 69,838

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Option Activity	The following table summarizes option activities during the nine months ended September 30, 2023: Schedule of Option Activity Weighted Average Weighted Average Remaining Aggregate Intrinsic Shares Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2023 3,425,000 $ 0.29 $ - Forfeited (200,000 ) 0.67 Outstanding and exercisable at September 30, 2023 3,225,000 0.27 2.11 $ -
Summary of Stock Options Outstanding	The following table summarizes information about options outstanding and exercisable at September 30, 2023: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 2.10 $ - $ 0.29 100,000 2.10 $ - $ 0.75 550,000 2.20 $ - $ 0.88 150,000 0.80 $ - 3,225,000 2.11 $ -
Schedule of Warrant Activity	The following table summarizes warrant activities during the nine months ended September 30, 2023: Schedule of Warrant Activity Number of Weighted Average Weighted Average Remaining Aggregate Intrinsic Warrants Exercise Price Life in Years Value Outstanding and exercisable at January 1, 2023 475,000 $ 0.97 Forfeited (37,500 ) 0.29 Outstanding and exercisable at September 30, 2023 437,500 $ 1.03 0.60 $ -
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding and exercisable at September 30, 2023: Summary of Warrants Outstanding Exercise Price Outstanding and Exercisable Weighted Average Intrinsic Value $ 0.29 50,000 0.29 $ - $ 1.00 18,000 0.64 $ - $ 1.12 366,000 0.64 $ - $ 2.00 3,500 0.64 $ - 437,500 0.60 $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 32,938 $ 50,784 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 130,422 Weighted Average Remaining Lease Term Operating leases 1 year 9 months 2 years 9 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2023 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2023 $ 12,497 2024 50,663 2025 25,668 Total lease payments 88,828 Less: amount representing imputed interest (3,968 ) Present value of lease liability 84,860 Less: current portion (47,146 ) Lease liability, non-current portion $ 37,714

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,410,207			$ 1,711,351			$ 1,410,207	$ 1,711,351	$ 1,431,707	$ 3,106,942
Restricted cash	1,042,957			1,644,321			1,042,957	1,644,321
Working capital deficit	7,579,249						7,579,249		$ 6,293,198
Net loss	$ 775,839	$ 835,062	$ 827,454	$ 713,267	$ 1,077,841	$ 1,030,922	2,438,355	2,822,030
Cash used in operations							$ 2,010,767	$ 2,286,682

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	128,636,885	118,243,675
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	437,500	487,500
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,225,000	3,425,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	113,841,427	105,081,847
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	817,766	8,602,376
2022 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	10,115,192	646,952

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Restricted cash	$ 1,042,957	$ 1,410,102
Insured limits	250,000
Cash in excess FDIC insured amount	$ 1,160,207	$ 1,181,707

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 611,646	$ 314,160
Accrued vacation	88,691	69,077
Accrued directors’ fees	2,234,339	1,945,589
Accrued other expenses	123,002	75,186
Total Other Accrued Expenses	$ 3,057,678	$ 2,404,012

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023
2021 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance	$ 525,000	$ 1,025,000	$ 1,075,000	$ 1,075,000
Conversion	(325,000)	(500,000)	(50,000)
Balance	200,000	525,000	1,025,000	200,000
2021 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance		500,000	550,000	550,000
Conversion		(500,000)	(50,000)
Balance			500,000
2021 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance	525,000	525,000	525,000	525,000
Conversion	(325,000)
Balance	200,000	525,000	525,000	200,000
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance	2,077,500	1,352,500	752,500	752,500
Conversion	(185,000)
Issued	900,000	725,000	600,000
Balance	2,792,500	2,077,500	1,352,500	2,792,500
2022 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance	75,000	75,000	75,000	75,000
Conversion
Issued	700,000
Balance	775,000	75,000	75,000	775,000
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance	2,002,500	1,277,500	677,500	677,500
Conversion	(185,000)
Issued	200,000	725,000	600,000
Balance	$ 2,017,500	$ 2,002,500	$ 1,277,500	$ 2,017,500

Schedule of Conversion of Notes

Schedule of Conversion of Notes into Preferred Stock (Details) - Series D-1 Convertible Preferred Stock [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2023 $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares
Short-Term Debt [Line Items]
Principal converted		$ 875,000
Accrued interest converted		70,466
Total converted		$ 945,466
Conversion price | $ / shares	$ 2.862	$ 2.862
Total shares | shares	122,725	330,354
2023 Conversions of 2022 Notes [Member]
Short-Term Debt [Line Items]
Principal converted		$ 185,000
Accrued interest converted		14,875
Total converted		$ 199,875
Conversion price | $ / shares	$ 2.862	$ 2.862
Total shares | shares	69,838	69,838

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Proceeds from notes payable		$ 700,000	$ 550,000
Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Aggregate amount	$ 351,239	$ 945,466
Number of shares	122,725	330,354
Conversion price	$ 2.862	$ 2.862
2021 Notes [Member]
Short-Term Debt [Line Items]
Proceeds from notes payable		$ 1,075,000
Proceeds from related party investor		525,000
2022 Note [Member]
Short-Term Debt [Line Items]
Proceeds from notes payable		2,977,500
Proceeds from related party investor		2,202,500
2023 Conversions of 2022 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Aggregate amount	$ 199,875	$ 199,875
Number of shares	69,838	69,838
Conversion price	$ 2.862	$ 2.862

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Note payable	$ 78,066	$ 239,394

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Director fees	$ 96,250	$ 96,250	$ 288,750	$ 288,750
Accrued director fees	2,234,339		2,234,339		$ 1,945,589
Mr. Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees	63,600	63,600	190,800	190,800
Director fees	18,750	$ 18,750	56,250	$ 56,250
Accrued director fees	412,500		412,500		356,250
Totalamount owed	$ 381,600		$ 381,600		$ 212,000

Schedule of Option Activity (De

Schedule of Option Activity (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of options outstanding and exercisable, beginning balace | shares	3,425,000
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 0.29
Stock options, forfeited | shares	(200,000)
Weighted average exercise price, forfeited | $ / shares	$ 0.67
Number of options outstanding and exercisable, ending balance | shares	3,225,000
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 0.27
Weighted Average Remaining Contractual Life, Exercisable	2 years 1 month 9 days
Intrinsic Value, Outstanding | $

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.27	$ 0.29
Outstanding	3,225,000	3,425,000
Weighted Average Remaining Contractual Life, Exercisable	2 years 1 month 9 days
Intrinsic Value, Outstanding
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding	3,225,000
Exercisable	3,225,000
Weighted Average Remaining Contractual Life, Outstanding	2 years 1 month 9 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 1 month 9 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range One [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.12
Exercise Price, Exercisable	$ 0.12
Outstanding	2,425,000
Exercisable	2,425,000
Weighted Average Remaining Contractual Life, Outstanding	2 years 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 1 month 6 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Two [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	100,000
Exercisable	100,000
Weighted Average Remaining Contractual Life, Outstanding	2 years 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 1 month 6 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Three [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.75
Exercise Price, Exercisable	$ 0.75
Outstanding	550,000
Exercisable	550,000
Weighted Average Remaining Contractual Life, Outstanding	2 years 2 months 12 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 2 months 12 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Four [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.88
Exercise Price, Exercisable	$ 0.88
Outstanding	150,000
Exercisable	150,000
Weighted Average Remaining Contractual Life, Outstanding	9 months 18 days
Weighted Average Remaining Contractual Life, Exercisable	9 months 18 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Equity [Abstract]
Warrants outstanding and exercisable, beginning balance | shares	475,000
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 0.97
Warrants, forfeited | shares	(37,500)
Weighted average exercise price, forfeited | $ / shares	$ 0.29
Warrants outstanding and exercisable, ending balance | shares	437,500
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 1.03
Weighted Average Remaining Contractual Life, Outstanding	7 months 6 days
Intrinsic Value | $

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding	437,500	475,000
Weighted Average Remaining Contractual Life, Outstanding	7 months 6 days
Intrinsic Value, Exercisable
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding	437,500
Exercisable	437,500
Weighted Average Remaining Contractual Life, Outstanding	7 months 6 days
Weighted Average Remaining Contractual Life, Exercisable	7 months 6 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	50,000
Exercisable	50,000
Weighted Average Remaining Contractual Life, Outstanding	3 months 14 days
Weighted Average Remaining Contractual Life, Exercisable	3 months 14 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 1
Exercise Price, Exercisable	$ 1
Outstanding	18,000
Exercisable	18,000
Weighted Average Remaining Contractual Life, Outstanding	7 months 20 days
Weighted Average Remaining Contractual Life, Exercisable	7 months 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 1.12
Exercise Price, Exercisable	$ 1.12
Outstanding	366,000
Exercisable	366,000
Weighted Average Remaining Contractual Life, Outstanding	7 months 20 days
Weighted Average Remaining Contractual Life, Exercisable	7 months 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Four [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 2
Exercise Price, Exercisable	$ 2
Outstanding	3,500
Exercisable	3,500
Weighted Average Remaining Contractual Life, Outstanding	7 months 20 days
Weighted Average Remaining Contractual Life, Exercisable	7 months 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($) shares
Class of Stock [Line Items]
Reverse stock split, description	to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
Series D-1 Convertible Preferred Stock [Member] | 2021 Notes [Member]
Class of Stock [Line Items]
Issuance of stock, shares | shares	330,354
Conversion of principal	$ 875,000
Conversion of accrued interest	$ 70,466
Series D-1 Convertible Preferred Stock [Member] | 2022 Notes [Member]
Class of Stock [Line Items]
Issuance of stock, shares | shares	69,838
Conversion of principal	$ 185,000
Conversion of accrued interest	$ 14,875

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 32,938	$ 50,784
Right-of-use assets obtained in exchange for lease obligations: Operating leases		$ 130,422
Weighted Average Remaining Lease Term: Operating leases	1 year 9 months	2 years 9 months
Weighted Average Discount Rate: Operating leases	5%
Minimum [Member]
Weighted Average Discount Rate: Operating leases		5%
Maximum [Member]
Weighted Average Discount Rate: Operating leases		8%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Leases
2023	$ 12,497
2024	50,663
2025	25,668
Total lease payments	88,828
Less: amount representing imputed interest	(3,968)
Present value of lease liability	84,860
Less: current portion	(47,146)	$ (44,422)
Lease liability, non-current portion	$ 37,714	$ 73,376

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($) ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 18, 2022 ft²
Research and Development Expense [Member]
Operating lease, expense	$ 8,373	$ 8,331		$ 25,826	$ 33,698
General and Administrative Expense [Member]
Operating lease, expense	4,187	4,166		12,913	16,850
Property Subject to Operating Lease [Member]
Operating lease, expense	$ 12,560	$ 12,497		38,739	$ 50,548
Knoxville, Tennessee [Member]
Area of land | ft²			4,500			2,700
Lessee, operating lease, term of contract			5 years			3 years
Rent expenses per month			$ 6,100
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month				4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month				$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 25, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Grants
Proceeds from grant	$ 2,500,000
Deferred revenue current		$ 1,074,358		$ 1,074,358		$ 1,510,958
Revenue		$ 69,733	$ 314,890	$ 436,600	$ 824,205

License Transactions (Details N

License Transactions (Details Narrative)	9 Months Ended
	Sep. 30, 2023
License Transactions
License transaction description	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company (i) paid $5,000 for the option to obtain an exclusive worldwide, royalty-bearing license that had an option expiration date of May 31, 2023, (ii) agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option, (iii) agreed to pay up to $25,000 of past UM patent expenses for this IP, and (iv) entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 14, 2023	Sep. 30, 2023	Sep. 30, 2023
Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of principal and interest			$ 875,000
Number of preferred stock converted		122,725	330,354
Conversion price		$ 2.862	$ 2.862
Subsequent Event [Member] | 2022 Note [Member]
Subsequent Event [Line Items]
Debt instrument face amount	$ 50,000
Subsequent Event [Member] | 2022 Note [Member] | Series D-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of principal and interest	$ 289,101
Number of preferred stock converted	101,061
Conversion price	$ 2.862